Navigation Links
Amylin Pharmaceuticals Reports First Quarter Financial Results
Date:4/18/2011

SAN DIEGO, April 18, 2011 /PRNewswire/ -- Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN) today reported financial results for the quarter ended March 31, 2011. The Company reported total revenue of $152.7 million for the quarter ended March 31, 2011, which includes net product sales of $150.8 million and revenues under collaborative agreements of $1.9 million. Non-GAAP operating loss was $3.2 million for the quarter ended March 31, 2011, compared to $3.8 million for the same period in 2010. GAAP net loss was $37.3 million, or $0.26 per share, for the quarter ended March 31, 2011, compared to $38.2 million, or $0.27 per share, for the same period in 2010. Net loss excluding restructuring charges was $34.5 million, or $0.24 per share for the quarter ended March 31, 2011, compared to $38.2 million, or $0.27 per share for the same period in 2010.  

At March 31, 2011 the Company held cash, cash equivalents, short-term investments and restricted cash of $475.2 million. The Company’s $200 million of 2.5% convertible senior notes were repaid subsequent to the end of the quarter on April 15, 2011. During the first quarter, the Company also notified its partner Eli Lilly and Company of its intent to draw a $165 million line of credit available from Lilly. These funds may be drawn in May of 2011, and, if drawn, the loan would be due in May 2014.

"We continue to manage the business with operational discipline and ended the quarter in a strong financial position that led to reduced expenses and improved gross margins," said Mark G. Foletta, senior vice president of finance and chief financial officer at Amylin Pharmaceuticals. "We remain focused on our longer-term target of generating sustainable positive operating cash flow and, we believe, that the significant cost-savings we have realized over the past two years reflect our ability to efficiently manage our business and
'/>"/>

SOURCE Amylin Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Amylin to Present Data Showing Investigational Metreleptin Treatment Led to Long-Term Improvements in Diabetes and Lipid Control in Patients with Lipodystrophy
2. Amylin and Takeda Voluntarily Suspend Clinical Activities in Obesity Trial
3. Amylin Pharmaceuticals to Present at the Barclays Capital 2011 Global Healthcare Conference
4. Amylin Pharmaceuticals to Present at the 2011 ISI Annual Conference
5. Amylin Pharmaceuticals Reports 2010 Financial Results
6. Amylin Pharmaceuticals to Webcast Year-End Financial Results
7. Amylin Pharmaceuticals to Present at the 29th Annual J.P. Morgan Healthcare Conference
8. Amylin Submits Clinical and Nonclinical Sections of Rolling Biologics License Application for Metreleptin to Treat Rare Forms of Lipodystrophy
9. Amylin Pharmaceuticals Reports Third Quarter Financial Results
10. Amylin Pharmaceuticals to Present at the 2010 Credit Suisse Healthcare Conference
11. Amylin, Lilly and Alkermes Announce Receipt of Complete Response Letter from FDA for BYDUREON™
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/17/2015)... , April 17, 2015  AbbVie Inc. ("AbbVie") (NYSE ... that it has extended the expiration of its exchange offer ... of Pharmacyclics, Inc. to 5 p.m., New York ... On April 17, 2015, AbbVie also voluntarily withdrew its ... Act in order to provide the FTC with additional time ...
(Date:4/17/2015)... Research and Markets ( http://www.researchandmarkets.com/research/6tdwh8/medical_device ... "Medical Device Outsourcing - Global Strategic Business Report" ... report analyzes the worldwide markets for Medical Device ... Categories: Class I, Class II, and Class III. ... Include - Radiology, Orthopedic, Neurology, Cardiology, and Others. ...
(Date:4/17/2015)... , April 17, 2015 ASSESS ... mutation   is a viable alternative to tumour biopsy   ... in all patients with advanced NSCLC   AstraZeneca ... of plasma circulating tumour DNA (ctDNA) testing for epidermal growth ... advanced non-small cell lung cancer (NSCLC) in clinical practice. [ ...
Breaking Medicine Technology:AbbVie Extends Exchange Offer to Acquire Pharmacyclics, Inc. 2AbbVie Extends Exchange Offer to Acquire Pharmacyclics, Inc. 3AbbVie Extends Exchange Offer to Acquire Pharmacyclics, Inc. 4Medical Device Outsourcing (Radiology, Orthopedic, Neurology, Cardiology, and Others) Market 2015 - Global Strategic Business Report 2Medical Device Outsourcing (Radiology, Orthopedic, Neurology, Cardiology, and Others) Market 2015 - Global Strategic Business Report 3"Real World" Data Support Use of Blood Test for EGFR Mutation in Advanced NSCLC 2"Real World" Data Support Use of Blood Test for EGFR Mutation in Advanced NSCLC 3"Real World" Data Support Use of Blood Test for EGFR Mutation in Advanced NSCLC 4
... 2007 - Ceragenix Pharmaceuticals,Inc. (OTCBB:CGXP), a biopharmaceutical ... announced that a catheter,treated with a Ceragenin ... 21 day study., In the study, polyurethane ... a phosphate-suffered solution along with an,untreated catheter. ...
... PGL; NASDAQ: PGLA) is pleased to announce that its ... late breaking news,presentation by the European Association for the ... the results of this liver,cancer trial at the American ... ,In expectation of having final data fully analysed and ...
Cached Medicine Technology:Ceragenix Announces Ceragenins Virtually Prevent Catheter Biofilm,Formation in 21 Day Study 2Ceragenix Announces Ceragenins Virtually Prevent Catheter Biofilm,Formation in 21 Day Study 3PI-88 Data to be Presented at Key International Conferences 2PI-88 Data to be Presented at Key International Conferences 3
(Date:4/18/2015)... Lower-auto-insurance.com has released a new blog post ... quotes . , Drivers can find accurate information ... professional insurance brokerage website can help drivers compare the ... convenient way. The whole process is designed to be ... online car insurance quotes is advantageous because it allows ...
(Date:4/18/2015)... York, New York (PRWEB) April 18, 2015 ... ) filed on behalf of individuals who were ... replacement system continue to move forward in the U.S. ... Order dated April 10th, the Court has amended an ... of unrelated cases. Among other things, the new amendment ...
(Date:4/18/2015)... 2015 More than 2000 styles of ... TheCelebrityDresses.com, the #1 online store carrying celebrity inspired special ... have got their perfect dresses for their prom. For ... prom dresses at TheCelebrityDresses.com would be an ideal choice. ... 2000 prom dresses inspired by the most loved styles ...
(Date:4/18/2015)... Aureus Medical Group (web: aureusmedical.com), a ... jobs, has announced that it will participate as ... Association Annual Conference to be held May 1-2, ... , The SCAPTA Annual Conference offers educational ... services. , Representatives from Aureus Medical’s ...
(Date:4/18/2015)... PHOENIX, ARIZONA – In March, Mark Ona, Territory ... destruction professionals across the United States, earned the professional ... display “CSDS” as a professional title with his name. ... of Information Destruction 2015 Annual Conference began - one ... 20 people who took the exam, Ona was amongst ...
Breaking Medicine News(10 mins):Health News:Auto Insurance Quotes Can Provide Accurate Results! 2Health News:DePuy Pinnacle Hip Lawsuits: Federal Litigation Amends Case Management Order to Allow for Joinder of Unrelated Claims 2Health News:DePuy Pinnacle Hip Lawsuits: Federal Litigation Amends Case Management Order to Allow for Joinder of Unrelated Claims 3Health News:Prom Dresses 2015 on Sale at TheCelebrityDresses.com 2Health News:Healthcare Staffing Leader, Aureus Medical Group, to Exhibit at the South Carolina Physical Therapy Association Annual Conference 2
... ... their families on the importance of early detection , ... Denver, CO (Vocus) December 2, 2009 -- Men, women, families, friends and neighbors – ... Rudolph Ramble 5K is a part of the national PACE Race Series , which was ...
... Dec. 2 Pro-abortion activists will lobby Washington on Wednesday, ... pro-life Stupak-Pitts Amendment. , Americans United for Life President ... the abortion lobby,s effort to expand taxpayer funding of abortion: ... and the abortion lobby actually demean women with their argument ...
... , KANSAS CITY, Mo., Dec. 2 ... practical view on proposed health reform legislation working through Congress. ... good, bad, and ugly in the legislation, according to Ed Fensholt ... Division and Lockton,s Health Reform Advisory Practice . ...
... are more likely to be advertised in magazines with ... adults, resulting in disproportionately high youth exposure to such ... Researchers at the Boston University School of Public Health, ... Media Resources who conducted the study -- published ...
... (OTC Bulletin Board: CSBR), a U.S. Oncology drug ... at accelerating the development and enhancing the value ... agreement with Ramot at Tel Aviv University Ltd., ... The licensing agreement encompasses the development ...
... , SAN DIEGO, ... diversified supplier of Farming, Nursery and Wellness products, is pleased ... the Cook,sware A,faire in Oakland, Calif., at the Oakland Zoo ... Farms, Inc. Customer Service Department at 877-90-FARMS or visit ...
Cached Medicine News:Health News:PACE Race Returns with Denver's Rudolph Ramble 2Health News:PACE Race Returns with Denver's Rudolph Ramble 3Health News:PACE Race Returns with Denver's Rudolph Ramble 4Health News:Lockton Outlines Implications of Proposed Health Reform Plans 2Health News:Alcohol companies target youths with magazine ads, new study shows 2Health News:Champions Biotechnology signs exclusive agreement with Tel Aviv University for cancer drug 2Health News:US Farms, Inc. Showcasing Aloe365(TM) Product Line at Cook'sware A'faire at Oakland Zoo 2
... CoaguChek System has been providing accurate, reliable PT/INR ... point of care. , The CoaguChek System is ... self-testing when monitoring on Coumadin (warfarin sodium) therapy. ... a result from a fingerstick drop (10ul) of ...
The QuickScreen Pro Multi Drug Screening Test is a rapid, self-timing, qualitative immunoassay for,the detection of drugs of abuse in urine....
... The ADC drugs of abuse tests are ... at the SAMHSA recommended cut-off as confirmed by ... result. A more specific alternative method (such as ... a confirmed result. Professional judgment should be applied ...
The Osteomark NTx Point of Care (POC)device allows physicians to monitor their patients response to anti-resorptive drugs as early as 3-6 months from starting treatment. Osteomark NTx shows you and y...
Medicine Products: